BPC-157
BPC-157 is a 15-amino-acid gastric peptide fragment with consistent preclinical repair data, including a 2025 sports-medicine systematic review of 36 studies with 35 preclinical studies and one clinical study, but no published large human efficacy RCT.
BPC-157 scored 6.4 / 10 (👍 Worth trying) on the BioHarmony scale as a Substance → Peptide → Growth / Repair Peptide.
What It Is
BPC-157 is a synthetic 15-amino-acid peptide modeled after a protective gastric protein fragment. It is best understood as an investigational repair peptide: the strongest case is not that it numbs pain, boosts performance directly, or replaces rehab, but that it may accelerate tissue repair signaling in tendon, ligament, muscle, gut mucosa, wounds, and nerve-injury models.
The most defensible summary is promising but unfinished. Vasireddi 2025 reviewed 36 orthopaedic sports-medicine studies and found 35 were preclinical and only one was clinical. McGuire 2025 reached the same practical conclusion: BPC-157 has robust preclinical momentum but remains investigational until well-designed human trials are completed. That is why the BioHarmony score holds at 7.3 instead of climbing higher.
Mechanistically, BPC-157 sits in the repair-signaling category. Sikiric 2018 supports vascular recruitment and gastrointestinal healing, Gwyer 2019 supports musculoskeletal soft-tissue repair, Chang 2014 supports growth-hormone receptor expression in tendon fibroblasts, and Hsieh 2017 supports VEGFR2/Akt/eNOS angiogenesis signaling. Newer Zhang 2026 work adds the FBXO22-BACH1 angiogenesis pathway. That makes the biology internally coherent, even though human outcomes are still not proven.
In practice, the main fork is route. Oral BPC-157 should mean arginine salt, usually for gut-focused use. Acetate salt is the community default for subcutaneous injection, usually near a soft-tissue injury. Both are gray-market in the United States. The FDA April 22, 2026 update says BPC-157 was removed from Category 2 because nominations were withdrawn, while PCAC review for BPC-157 acetate and free base is scheduled for July 23, 2026. BPC-157 is still not FDA-approved, and the WADA prohibited list makes it off-limits for tested athletes.
Terminology
- BPC: Body Protective Compound. The research shorthand behind BPC-157.
- BPC-157: A 15-amino-acid synthetic peptide fragment based on a gastric protective protein.
- Arginine salt: Oral BPC-157 form used in capsule protocols because it is considered more suitable for GI transit.
- Acetate salt: Common injectable BPC-157 form sold as lyophilized vials.
- SC: Subcutaneous injection into fat below the skin.
- IM: Intramuscular injection into muscle.
- NO: Nitric oxide, a short-lived signaling gas involved in blood-flow regulation.
- eNOS: Endothelial nitric oxide synthase, the blood-vessel enzyme that produces nitric oxide.
- VEGF: Vascular endothelial growth factor, a signal that promotes new blood-vessel growth.
- VEGFR2: Vascular endothelial growth factor receptor 2, a receptor involved in angiogenesis.
- Angiogenesis: Formation of new blood vessels. Useful for repair, concerning in cancer or proliferative retinopathy contexts.
- GHR: Growth hormone receptor. BPC-157 has preclinical tendon-fibroblast data involving GHR expression.
- NSAID: Nonsteroidal anti-inflammatory drug, such as ibuprofen or naproxen.
- PCAC: Pharmacy Compounding Advisory Committee, the FDA advisory committee involved in evaluating some bulk drug substances.
- WADA S0: World Anti-Doping Agency class for non-approved substances prohibited in sport.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 4 routes and 5 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral (arginine salt capsule) | Arginine-salt capsule, usually 250 to 500 mcg | No established approved clinical dose; small human safety work does not define efficacy dosing | 250 to 500 mcg once or twice daily, most often for gut-focused protocols |
| Subcutaneous injection (acetate salt) | Lyophilized acetate vial reconstituted in bacteriostatic water | No approved clinical dosing range | 250 to 500 mcg once or twice daily, often injected near the target injury |
| Intramuscular injection | Reconstituted peptide injected into muscle | No approved clinical dosing range | 250 to 500 mcg daily, less commonly used than subcutaneous injection |
| Topical / intranasal (gray-market) | Compounded cream around 1 mcg/g, or nasal spray | No approved clinical dosing range | Topical 1 mcg/g for local wounds; intranasal 200 to 500 mcg daily in community protocols |
Protocols
Acute soft-tissue recovery Mixed
- Dose
- 250 to 500 mcg SC 1 to 2x/day near injury site
- Frequency
- 1 to 2x/day
- Duration
- 4 to 8 weeks
Most common use case. Use with progressive rehab, load management, protein adequacy, and sleep rather than as a replacement.
Maintenance / longevity Anecdotal
- Dose
- 200 to 250 mcg SC 1x/day
- Frequency
- Daily
- Duration
- 4 weeks on / 2 weeks off
No lifespan data and no clinical need for maintenance use. Conservative cycling is a community habit, not a trial-derived rule.
Post-surgery recovery Anecdotal
- Dose
- 250 to 500 mcg SC 2x/day
- Frequency
- 2x/day
- Duration
- 2 to 6 weeks, commonly starting after the acute surgical window
Discuss with the surgeon. Avoid around cancer surgery or uncertain graft/angiogenesis contexts unless a clinician explicitly clears it.
GI / IBD protocol Mixed
- Dose
- 250 to 500 mcg oral arginine-salt 2x/day
- Frequency
- 2x/day
- Duration
- 4 to 12 weeks
Oral route is intentional for GI mucosal exposure. There is no verified controlled human IBD trial in the supplied audit.
Stacked with TB-500 Anecdotal
- Dose
- 250 to 500 mcg BPC-157 SC daily plus 2 to 2.5 mg TB-500 SC 2x/week
- Frequency
- Daily BPC-157 plus twice-weekly TB-500
- Duration
- 4 to 6 weeks
Popular soft-tissue combo. Synergy rests on mechanism and community experience, not controlled human comparison.
Use-Case Specific Dosing
| Use Case | Dose | Notes |
|---|---|---|
How this score is calculated →
Upside contribution: 3.73
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 4.3 | 1.075 | |
| Breadth of Benefits | 15% | 4.0 | 0.600 | |
| Evidence Quality | 25% | 3.0 | 0.750 | |
| Speed of Onset | 10% | 3.5 | 0.350 | |
| Durability | 10% | 3.5 | 0.350 | |
| Bioindividuality Upside | 15% | 4.0 | 0.600 | |
| Total | 3.725 |
Upside Rationale
BPC-157 has its best upside when the user matches BPC-157 to the evidence-backed lane instead of treating it as a broad wellness shortcut. The upside is breadth across tissue-repair models, especially gut, tendon, ligament, muscle, vascular, and nerve injury biology. The evidence repeatedly points toward cytoprotection, blood-flow support, and repair signaling, which explains the high use-case scores for injury recovery and gut health. The catch is translation: impressive animal data still has to survive controlled human trials. The most useful anchors are Vasireddi 2025 and Gwyer 2019, because they explain both the signal and the boundary around that signal. For readers, the so-what is simple: BPC-157 is worth considering when the expected benefit can be observed in a concrete marker, symptom, lab, or performance measure. BPC-157 is weaker when the goal is vague optimization with no baseline and no follow-up.
Efficacy (4.3/5.0). BPC-157 earns a high efficacy score because the animal repair signal is unusually consistent, not because human efficacy is proven. Gwyer 2019 supports musculoskeletal soft-tissue repair across tendon, ligament, and muscle models, while Japjec 2021 supports myotendinous-junction repair in rats. GI and wound evidence also repeat across reviews, including Sikiric 2018 and Seiwerth 2021. The user signal is large and directionally consistent across sports-recovery communities, but it remains unblinded and gray-market. The 4.3 score preserves v0 because new 2025 to 2026 reviews reinforce the same pattern without adding a large human RCT.
Breadth of benefits (4.0/5.0). BPC-157 covers one of the broader repair surfaces in the peptide category: tendon, ligament, skeletal muscle, myotendinous junction, gut mucosa, gastric and NSAID injury, wound closure, nerve repair, vascular protection, and central nervous system injury models. Matek 2026 specifically expands the musculoskeletal framing across tendon, ligament, muscle, osteotendinous, myotendinous, and muscle-to-bone junctions. Jozwiak 2025 supports the multifunctionality frame while keeping it preclinical-heavy. Breadth is capped at 4.0 because it is not breadth across confirmed human indications. It is breadth across animal models, mechanisms, and community use cases.
Evidence quality (3.0/5.0). BPC-157 evidence quality is the limiting factor: the 2024 to 2026 audit found no meta-analysis and no RCT with at least 100 participants. Vasireddi 2025 included 36 studies, but 35 were preclinical and one was clinical. Lee 2025 is useful only as a two-person IV tolerability pilot, not an efficacy trial. The corrected citation record improves hygiene: Sikiric 2018 and Gwyer 2019 are now linked to the right PMIDs. Still, there is no Cochrane review, no orthopedic society guideline, no NICE appraisal, and no FDA approval.
Speed of onset (3.5/5.0). BPC-157 appears fast for injury-related symptoms, slower for structural repair, and uncertain for gut or neurological goals. Community soft-tissue reports commonly cluster around 7 to 14 days for pain and range-of-motion changes, while the more credible repair-cycle framing is 4 to 8 weeks. Preclinical wound, tendon, and junction models support the idea that BPC-157 acts during early repair biology rather than after months of remodeling. Gut protocols are usually framed as 4 to 12 weeks, but no verified controlled human IBD trial was available in the supplied audit. The score stays 3.5 because onset looks faster than collagen supplements or cartilage protocols, but not acute like analgesics.
Durability (3.5/5.0). BPC-157 has better durability for acute injury cycles than for chronic disease maintenance. If BPC-157 helps tissue remodel, the finished repair can persist after the peptide is stopped. That is different from symptom masking. Chronic conditions are less durable because the upstream driver may remain active: inflammatory bowel disease, degenerative joint disease, poor loading mechanics, under-recovery, or repeated trauma. The short plasma exposure also argues against a permanent pharmacologic state. A 3.5 score reflects a practical split: acute-injury gains may stick when the tissue truly heals, while chronic-protection effects likely fade after discontinuation.
Bioindividuality (4.0/5.0). BPC-157 seems broadly applicable when the limiting factor is repair biology, but real-world response probably depends on diagnosis quality. A partial tendon tear, a fresh surgical wound, a gut-mucosal irritation pattern, and chronic nonspecific pain are not the same target. Product purity, salt form, route, sterile technique, sleep, protein intake, mechanical loading, and rehab quality all change outcomes. Cancer history, pre-malignant lesions, proliferative retinopathy, anticoagulation, pregnancy, and WADA testing change the risk calculus. The score stays 4.0 because non-responder reports are comparatively uncommon in community use, but expectation effects and unblinded self-selection are built into that observation.
Downside contribution: 2.30 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 2.0 | 0.600 | |
| Side Effect Profile | 15% | 2.0 | 0.300 | |
| Financial Cost | 5% | 1.5 | 0.075 | |
| Time/Effort Burden | 5% | 2.5 | 0.125 | |
| Opportunity Cost | 5% | 2.0 | 0.100 | |
| Dependency / Withdrawal | 15% | 1.0 | 0.150 | |
| Reversibility | 25% | 1.5 | 0.375 | |
| Total | 1.725 | |||
| Harm subtotal × 1.4 | 1.995 | |||
| Opportunity subtotal × 1.0 | 0.300 | |||
| Combined downside | 2.295 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.955 |
Downside Rationale
BPC-157's main downside is not one isolated risk; it is the mismatch between marketing certainty and the actual evidence base. The downside is uncertainty. BPC-157 is commonly sold in gray-market peptide channels, dosing is not standardized, long-term immune or cancer-adjacent safety is unsettled, and the human evidence base is thin. BPC-157 should be framed as a tracked, clinician-aware experiment rather than a casual daily supplement. Lee 2025 is the anchor that keeps the safety discussion honest, while Vasireddi 2025 helps define where the benefits are strongest. The practical move is to treat BPC-157 as a targeted experiment, not a default habit. That means checking contraindications, product quality, dose, medication conflicts, and the opportunity cost of skipping better-supported basics before assigning BPC-157 a permanent role.
Safety risk (2.0/5.0). BPC-157 has no large controlled human safety database, so safety should be framed as uncertain rather than reassuring. Lee 2025 reported no safety signal in two adults receiving IV infusion, but that is too small to resolve chronic use, injection, cancer-risk, pregnancy, or immune-response questions. FDA's prior concern profile included limited route-specific safety information, peptide impurities, active pharmaceutical ingredient characterization, and immunogenicity. The April 22, 2026 FDA update changed Category 2 status after nomination withdrawal, not because BPC-157 became clinically endorsed. The practical worst-case concern is contaminated gray-market product or angiogenesis in the wrong biological context.
Side effect profile (2.0/5.0). BPC-157 side effects are usually mild in community reports, but the denominator is not controlled. Injection-site redness, bruising, soreness, and sterility errors are the most common practical issues. A smaller cluster reports transient palpitations, anxiety, lightheadedness, or cardiovascular-feeling effects, which fits the nitric-oxide and vascular-signaling frame without proving causality. Oral arginine-salt capsules appear easier to tolerate for most users, but product quality varies. No chronic side-effect syndrome is established, yet absence of proof is not proof of absence. This stays at 2.0 because reported effects are usually reversible, while long-term surveillance is weak.
Financial cost (1.5/5.0). BPC-157 is inexpensive compared with most regenerative medicine interventions. A typical gray-market cycle often lands around $40 to $80 per month before supplies, although pricing varies by vendor, testing, and dose. Serious users should budget for bacteriostatic water, syringes, alcohol swabs, sharps disposal, and ideally third-party purity testing. That still costs far less than surgery, repeated imaging, or months of physical therapy, but the low price is paired with a sourcing problem: cheap gray-market peptide is not the same as verified pharmaceutical quality. The score stays low because the absolute financial burden is modest.
Time / effort burden (2.5/5.0). BPC-157 asks more effort than a capsule-only supplement when injected. Subcutaneous protocols require reconstitution, sterile technique, injection-site rotation, refrigeration, sharps handling, and consistent daily or twice-daily dosing for 4 to 8 weeks. Oral arginine salt is much easier and better suited to gut protocols, but oral use is not the default for many vendors and users need to verify the salt form. The effort score stays 2.5 because the protocol is bounded and learnable, but the sterile-technique burden is real. Anyone unwilling to handle injections carefully should avoid injectable BPC-157.
Opportunity cost (2.0/5.0). BPC-157 usually complements the basics rather than replacing them, but peptide curiosity can distract from the work that actually drives recovery. Load management, progressive rehab, sleep, protein intake, calories, collagen or gelatin plus vitamin C timing, and medical diagnosis still come first. BPC-157 is most reasonable when a user has already handled those basics or needs a short recovery-focused experiment. The opportunity cost rises when someone uses it to train through pain, delay imaging, skip physical therapy, or avoid surgical consultation. It also rises for athletes, because WADA status can make the career cost far larger than the peptide cost.
Dependency / withdrawal (1.0/5.0). BPC-157 has no established dependency or withdrawal pattern. It is not psychoactive in a reinforcing way, and there is no known receptor-downregulation syndrome from cycling on and off. Users typically stop after a repair cycle without rebound below baseline. If pain returns, the more likely explanation is unresolved injury mechanics, an incomplete diagnosis, or a chronic disease process rather than peptide withdrawal. This dimension stays at the floor because dependency risk is one of the cleaner parts of the profile, even though long-term safety remains incomplete.
Reversibility (1.5/5.0). BPC-157 effects appear mostly reversible after discontinuation, with one important distinction: tissue that heals during the cycle remains healed because the tissue changed, not because the peptide is still active. Ongoing vascular, nitric-oxide, inflammatory, or protective effects should fade after dosing stops. No permanent alteration to VEGFR2, eNOS, growth-hormone receptor expression, or monoamine systems has been established in humans. Reversibility is scored near the floor because BPC-157 is a short-cycle peptide intervention, not a surgery, implant, ablation, or permanent endocrine suppression strategy.
Verdict
BPC-157 is a 6.4/10 fit for adults considering an investigational recovery peptide after basic rehab, sleep, protein, and load management are already handled, not a proven human longevity or injury cure. The cleanest evidence anchors are Vasireddi 2025, which reviewed 36 sports-medicine studies and found 35 were preclinical plus one clinical study, and Gwyer 2019, which supports the tendon, ligament, and muscle repair direction in animal work. Lee 2025 adds useful context: reported a tiny two-person IV safety pilot that cannot answer efficacy. The practical gap is the same one that shows up across the report: mechanism and early outcomes are more convincing than broad real-world certainty. In practice, BPC-157 belongs after the basics, works best when the target is specific, and deserves tracking around benefits, side effects, interactions, and cost before it becomes a standing protocol.
✅ Best for: Healthy adults with acute soft-tissue injuries, stubborn tendon or ligament recovery, muscle strains, wound-healing goals, or post-surgical recovery questions where standard care is already handled and a clinician is not concerned about angiogenesis or clotting risk. BPC-157 is most defensible as a short, scoped repair experiment layered on top of rehab, sleep, adequate protein, load management, and diagnostic clarity. Oral arginine salt is the cleaner choice for gut-focused self-experimentation, while subcutaneous acetate is the common community route for local injury protocols. Non-tested athletes and experienced peptide users should still verify product purity.
❌ Avoid if: You have current cancer, a cancer history that makes angiogenesis concerning, pre-malignant lesions, proliferative retinopathy, pregnancy, planned pregnancy, breastfeeding, therapeutic anticoagulation, unexplained pain that has not been diagnosed, or any reason sterile injection technique is unrealistic. Avoid BPC-157 if you compete under WADA rules, because BPC-157 is prohibited under S0 non-approved substances. Also avoid if you need guideline-backed medical care for ulcerative colitis, tendon rupture, neurological injury, chronic pain, or post-surgical complications. BPC-157 may be promising, but it is not standard of care.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Injury Recovery: 9.0/10
Score: 9.0/10BPC-157 injury recovery earns 9.0/10 because Vasireddi 2025 anchors the most relevant signal. BPC-157 fits injury recovery when the target is tissue repair, vascular recruitment, or inflammation control, but the case still rests mostly on preclinical models. The score stays bounded because human trials are still sparse and most benefits come from animal or cell models. In practice, BPC-157 is most defensible when someone tracks pain, range of motion, swelling, sleep, training load, and clinician-tracked healing milestones instead of relying on a vague before-and-after feeling. BPC-157 is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a higher-risk recovery experiment with clear stop rules.
Gut Health / Microbiome: 9.0/10
Score: 9.0/10BPC-157 gut health earns 9.0/10 because Vasireddi 2025 anchors the most relevant signal. BPC-157 fits gut health when the target is tissue repair, vascular recruitment, or inflammation control, but the case still rests mostly on preclinical models. The score stays bounded because human trials are still sparse and most benefits come from animal or cell models. In practice, BPC-157 is most defensible when someone tracks pain, range of motion, swelling, sleep, training load, and clinician-tracked healing milestones instead of relying on a vague before-and-after feeling. BPC-157 is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a higher-risk recovery experiment with clear stop rules.
Recovery / Repair: 8.5/10
Score: 8.5/10BPC-157 recovery repair earns 8.5/10 because Vasireddi 2025 anchors the most relevant signal. BPC-157 fits recovery repair when the target is tissue repair, vascular recruitment, or inflammation control, but the case still rests mostly on preclinical models. The score stays bounded because human trials are still sparse and most benefits come from animal or cell models. In practice, BPC-157 is most defensible when someone tracks pain, range of motion, swelling, sleep, training load, and clinician-tracked healing milestones instead of relying on a vague before-and-after feeling. BPC-157 is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a higher-risk recovery experiment with clear stop rules.
Wound Healing: 8.5/10
Score: 8.5/10BPC-157 wound healing earns 8.5/10 because Vasireddi 2025 anchors the most relevant signal. BPC-157 fits wound healing when the target is tissue repair, vascular recruitment, or inflammation control, but the case still rests mostly on preclinical models. The score stays bounded because human trials are still sparse and most benefits come from animal or cell models. In practice, BPC-157 is most defensible when someone tracks pain, range of motion, swelling, sleep, training load, and clinician-tracked healing milestones instead of relying on a vague before-and-after feeling. BPC-157 is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a higher-risk recovery experiment with clear stop rules.
Nerve Regeneration: 7.5/10
Score: 7.5/10BPC-157 nerve regeneration earns 7.5/10 because Vasireddi 2025 anchors the most relevant signal. BPC-157 fits nerve regeneration when the target is tissue repair, vascular recruitment, or inflammation control, but the case still rests mostly on preclinical models. The score stays bounded because human trials are still sparse and most benefits come from animal or cell models. In practice, BPC-157 is most defensible when someone tracks pain, range of motion, swelling, sleep, training load, and clinician-tracked healing milestones instead of relying on a vague before-and-after feeling. BPC-157 is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a higher-risk recovery experiment with clear stop rules.
Neuroprotection: 7.5/10
Score: 7.5/10BPC-157 neuroprotection earns 7.5/10 because Vasireddi 2025 anchors the most relevant signal. BPC-157 fits neuroprotection when the target is tissue repair, vascular recruitment, or inflammation control, but the case still rests mostly on preclinical models. The score stays bounded because human trials are still sparse and most benefits come from animal or cell models. In practice, BPC-157 is most defensible when someone tracks pain, range of motion, swelling, sleep, training load, and clinician-tracked healing milestones instead of relying on a vague before-and-after feeling. BPC-157 is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a higher-risk recovery experiment with clear stop rules.
Bone / Joint Health: 5.5/10
Score: 5.5/10BPC-157 bone joint earns 5.5/10 because Vasireddi 2025 anchors the most relevant signal. BPC-157 fits bone joint when the target is tissue repair, vascular recruitment, or inflammation control, but the case still rests mostly on preclinical models. The score stays bounded because human trials are still sparse and most benefits come from animal or cell models. In practice, BPC-157 is most defensible when someone tracks pain, range of motion, swelling, sleep, training load, and clinician-tracked healing milestones instead of relying on a vague before-and-after feeling. BPC-157 is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a higher-risk recovery experiment with clear stop rules.
Anti-Inflammatory: 7.0/10
Score: 7.0/10BPC-157 anti inflammatory earns 7.0/10 because Vasireddi 2025 anchors the most relevant signal. BPC-157 fits anti inflammatory when the target is tissue repair, vascular recruitment, or inflammation control, but the case still rests mostly on preclinical models. The score stays bounded because human trials are still sparse and most benefits come from animal or cell models. In practice, BPC-157 is most defensible when someone tracks pain, range of motion, swelling, sleep, training load, and clinician-tracked healing milestones instead of relying on a vague before-and-after feeling. BPC-157 is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a higher-risk recovery experiment with clear stop rules.
Traumatic Brain Injury: 7.0/10
Score: 7.0/10BPC-157 tbi earns 7.0/10 because Vasireddi 2025 anchors the most relevant signal. BPC-157 fits tbi when the target is tissue repair, vascular recruitment, or inflammation control, but the case still rests mostly on preclinical models. The score stays bounded because human trials are still sparse and most benefits come from animal or cell models. In practice, BPC-157 is most defensible when someone tracks pain, range of motion, swelling, sleep, training load, and clinician-tracked healing milestones instead of relying on a vague before-and-after feeling. BPC-157 is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a higher-risk recovery experiment with clear stop rules.
Cardiovascular: 6.5/10
Score: 6.5/10BPC-157 cardiovascular earns 6.5/10 because Vasireddi 2025 anchors the most relevant signal. BPC-157 fits cardiovascular when the target is tissue repair, vascular recruitment, or inflammation control, but the case still rests mostly on preclinical models. The score stays bounded because human trials are still sparse and most benefits come from animal or cell models. In practice, BPC-157 is most defensible when someone tracks pain, range of motion, swelling, sleep, training load, and clinician-tracked healing milestones instead of relying on a vague before-and-after feeling. BPC-157 is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a higher-risk recovery experiment with clear stop rules.
Liver / Detoxification: 6.5/10
Score: 6.5/10BPC-157 liver detox earns 6.5/10 because Vasireddi 2025 anchors the most relevant signal. BPC-157 fits liver detox when the target is tissue repair, vascular recruitment, or inflammation control, but the case still rests mostly on preclinical models. The score stays bounded because human trials are still sparse and most benefits come from animal or cell models. In practice, BPC-157 is most defensible when someone tracks pain, range of motion, swelling, sleep, training load, and clinician-tracked healing milestones instead of relying on a vague before-and-after feeling. BPC-157 is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a higher-risk recovery experiment with clear stop rules.
Acute Pain Relief: 6.5/10
Score: 6.5/10BPC-157 acute pain earns 6.5/10 because Vasireddi 2025 anchors the most relevant signal. BPC-157 fits acute pain when the target is tissue repair, vascular recruitment, or inflammation control, but the case still rests mostly on preclinical models. The score stays bounded because human trials are still sparse and most benefits come from animal or cell models. In practice, BPC-157 is most defensible when someone tracks pain, range of motion, swelling, sleep, training load, and clinician-tracked healing milestones instead of relying on a vague before-and-after feeling. BPC-157 is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a higher-risk recovery experiment with clear stop rules.
Chronic Pain Management: 5.5/10
Score: 5.5/10BPC-157 chronic pain earns 5.5/10 because Vasireddi 2025 anchors the most relevant signal. BPC-157 fits chronic pain when the target is tissue repair, vascular recruitment, or inflammation control, but the case still rests mostly on preclinical models. The score stays bounded because human trials are still sparse and most benefits come from animal or cell models. In practice, BPC-157 is most defensible when someone tracks pain, range of motion, swelling, sleep, training load, and clinician-tracked healing milestones instead of relying on a vague before-and-after feeling. BPC-157 is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a higher-risk recovery experiment with clear stop rules.
| Use Case | Score | Summary |
|---|---|---|
| ○ Muscle Growth / Hypertrophy | 4.5 | Accelerates muscle fiber repair; indirect support for training recovery. BPC-157 is not a proven hypertrophy agent, and WADA status should keep tested athletes away from performance-framed use. |
| ○ Flexibility / Mobility | 4.0 | Tendon and ligament repair may restore range of motion when mobility is limited by injury. The evidence does not support using BPC-157 as a general flexibility enhancer in otherwise healthy tissue. |
| ○ Mood / Emotional Regulation | 4.0 | Dopaminergic and serotonergic system interactions in animal models. Human mood evidence is not established, so this remains an exploratory neurochemical score rather than a depression or anxiety treatment claim. |
| ○ Skin / Beauty | 4.0 | Wound healing and collagen synthesis support skin repair, especially in injury or wound contexts. It is not a cosmetic skin intervention with human photoaging trials, unlike red light therapy or retinoids. |
| ○ Healthspan | 4.0 | Broad tissue-protective effects support healthy aging in theory. No human healthspan trial exists, so this score reflects repair relevance in aging populations, not longevity proof. |
| ○ Geriatric / Aging Population | 4.0 | Healing acceleration is particularly valuable in aging populations. Older adults also face higher cancer, vascular, anticoagulation, and polypharmacy risk, so the caution bar is higher. |
| ○ Depression | 3.5 | Modulates dopamine and serotonin systems in animal work; limited direct evidence. No human depression RCT was identified in the audit, so standard mental-health care remains primary. |
| ○ Anxiety | 3.5 | GABAergic and serotonergic modulation; anxiolytic effects in some animal models. Human anxiety evidence is missing, and occasional user reports of palpitations or anxiety push this score down. |
| ○ Energy / Fatigue | 3.5 | Indirect via reduced inflammation and improved tissue function. Energy claims are secondary and should be interpreted as feeling better after an injury heals, not direct mitochondrial stimulation. |
| ○ Immune Function | 3.5 | Immunomodulatory; balances immune response rather than stimulating. The safety gap matters here because peptide immunogenicity and route-specific immune reactions were part of FDA's concern history. |
| ○ Cognition / Focus | 3.5 | Neuroprotective effects may support cognitive function indirectly in injury models. There is no direct healthy-adult focus trial, so cognition claims should remain conservative. |
| ○ Longevity / Lifespan | 3.5 | Tissue repair and cytoprotection; no lifespan studies. Maintenance use for longevity is community practice without trial support. |
| ○ Hormonal / Endocrine | 3.0 | Limited evidence; some interaction with growth hormone receptor expression in tendon fibroblasts. Chang 2014 supports local tendon-cell signaling, not systemic hormone optimization. |
| ○ Memory | 3.0 | Dopaminergic protection may preserve memory circuits in animal models. No human memory endpoint is verified in the audit. |
| ○ Stress / Resilience | 3.0 | Tissue-level stress protection; limited systemic stress data. BPC-157 may protect injured tissue from inflammatory or toxic stress, but it is not a validated stress-resilience protocol. |
| ○ Antioxidant / Oxidative Stress | 3.0 | Reduces oxidative stress markers in tissue injury models. The effect is better framed as cytoprotection inside injury models than as a broad antioxidant supplement. |
| ○ Strength / Power | 3.0 | Supports training via faster recovery from musculoskeletal injury. BPC-157 is not proven to directly increase strength or power output. |
| ○ Neuroplasticity | 3.0 | Nerve growth factor interactions; limited direct evidence. Preclinical nerve repair does not establish broad cognitive or skill-learning plasticity. |
Frequently Asked Questions
How does BPC-157 actually work at the cellular level?
BPC-157 appears to work through repair signaling rather than pain masking. Chang 2014 supports growth-hormone receptor expression in tendon fibroblasts, Hsieh 2017 supports VEGFR2/Akt/eNOS angiogenesis signaling, and Zhang 2026 adds the FBXO22-BACH1 vascular-repair pathway. These are mostly cell and animal data, so the mechanism is credible but not clinically proven.
What is the difference between BPC-157 arginine salt and acetate salt?
Arginine salt is the form used for oral BPC-157 capsules; acetate salt is generally treated as injection-only. The practical distinction is route selection: oral arginine salt for gut protocols, subcutaneous acetate for soft-tissue protocols. Most gray-market vendors sell acetate vials by default, so oral buyers need to verify the salt form rather than assume all BPC-157 products behave the same.
How do you dose BPC-157 for injury versus gut healing?
Community injury protocols usually use 250 to 500 mcg subcutaneous one to two times daily near the target injury for 4 to 8 weeks. Gut protocols usually use 250 to 500 mcg oral arginine salt twice daily for 4 to 12 weeks. These are not FDA-approved clinical doses. The evidence base supports repair potential, but Vasireddi 2025 found the sports-medicine literature remains overwhelmingly preclinical.
What is the evidence for BPC-157 in tendon and soft-tissue repair?
The soft-tissue evidence is strong in animals and weak in humans. Gwyer 2019 synthesized BPC-157's role in musculoskeletal soft-tissue healing, and Matek 2026 reinforces the tendon, ligament, muscle, myotendinous, and muscle-to-bone preclinical pattern. But the clinical gap remains: no large human tendon-healing RCT was found in the audit trail.
What is the evidence for BPC-157 in gut and IBD conditions?
GI is BPC-157's original evidence lane, but human IBD proof is still missing. Sikiric 2018 supports vascular recruitment and gastrointestinal healing in preclinical work, while Sikiric/Drmic 2013 supports NSAID-toxicity counteraction. The audit could not verify the claimed interstitial-cystitis pilot source, so it should not be used as a clean human-efficacy citation.
Is BPC-157 safe if there are no large human trials?
BPC-157 safety is uncertain, not proven clean. Lee 2025 reported no safety signal in a two-person IV pilot, which is useful but far too small for long-term conclusions. Main practical risks are gray-market contamination, injection reactions, immune response, transient palpitations or anxiety in sensitive users, and angiogenesis-related caution in cancer, pre-malignant lesions, or proliferative retinopathy.
What is the regulatory and legal status of BPC-157?
BPC-157 is not FDA-approved for any therapeutic use and is prohibited for WADA-tested athletes. The FDA April 22, 2026 update removed BPC-157 from Category 2 because nominations were withdrawn, while scheduling PCAC discussion for BPC-157 acetate and free base on July 23, 2026. WADA's prohibited-list page lists BPC-157 under S0 non-approved substances.
Can you stack BPC-157 with TB-500 for recovery?
The BPC-157 plus TB-500 stack is common in gray-market peptide practice, but it is not RCT-proven. The rationale is complementary repair signaling: BPC-157 is framed around nitric oxide, angiogenesis, and tissue protection, while TB-500 is framed around cell migration and actin remodeling. Common protocols pair daily BPC-157 with twice-weekly TB-500 for 4 to 6 weeks. Treat synergy as a hypothesis, not a clinical fact.
How fast should BPC-157 work?
Soft-tissue users often report pain and range-of-motion changes within 7 to 14 days, while tissue remodeling cycles are usually planned for 4 to 8 weeks. Gut protocols are commonly framed as 4 to 12 weeks. Those timelines come from animal repair kinetics and community use, not large human RCTs. If there is no change after a focused cycle, reassess diagnosis, loading, imaging, rehab, and product quality.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimensions changed | New score |
|---|---|---|
| First well-powered Phase 2 RCT confirms clinically meaningful tendon or ligament repair | Efficacy 4.3 to 4.5; Evidence 3.0 to 4.0 | 7.4 / 10 💪 Strong recommend |
| Long-term registry finds a cancer-incidence signal in chronic or high-risk users | Safety 2.0 to 4.0 | 4.9 / 10 🟡 Neutral |
| FDA completes PCAC review and a clear legal compounding path emerges without new safety restrictions | Evidence 3.0 to 3.5 | 7.0 / 10 💪 Strong recommend |
| Gray-market contamination scandal causes confirmed human harms | Safety 2.0 to 3.5 | 5.4 / 10 👍 Worth trying |
| Head-to-head human trial fails to beat placebo for tendon healing | Efficacy 4.3 to 3.0; Evidence 3.0 to 3.5 | 5.6 / 10 👍 Worth trying |
| Independent human GI trial confirms oral arginine-salt benefit in inflammatory bowel disease adjunct care | Breadth 4.0 to 4.3; Evidence 3.0 to 3.7 | 7.2 / 10 💪 Strong recommend |
Key Evidence Sources
- Vasireddi et al. 2025 - Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review, HSS Journal. 36 included studies; 35 preclinical and one clinical; concludes musculoskeletal promise but major human evidence and safety gaps
- Matek et al. 2026 - Tendon, Ligament, and Muscle Injury, Osteotendinous, Myotendinous, and Muscle-to-Bone Junction Therapy Perspectives with Growth Factors and Stable Gastric Pentadecapeptide BPC 157 - A Review, Pharmaceuticals. 2026 review reinforces consistent preclinical tendon, ligament, muscle, and junction repair findings while noting clinical validation remains pending
- McGuire et al. 2025 - Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing, Current Reviews in Musculoskeletal Medicine. Human evidence is extremely limited; BPC-157 should remain investigational until well-designed human trials are completed
- Jozwiak et al. 2025 - Multifunctionality and Possible Medical Application of the BPC 157 Peptide - Literature and Patent Review, Pharmaceuticals. Literature and patent review describes broad preclinical mechanisms and possible applications but does not close the human efficacy gap
- Lee 2025 - Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study, Alternative Therapies in Health and Medicine. Two-person IV infusion pilot reported no adverse effects up to 20 mg; too small for efficacy or robust safety conclusions
- Sikiric et al. 2018 - Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing, Current Pharmaceutical Design. Corrected PMID for v0 mismatch; supports broad GI, cytoprotective, and vascular-recruitment preclinical claims
- Gwyer et al. 2019 - Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing, Cell and Tissue Research. Corrected PMID for v0 mismatch; supports preclinical tendon, ligament, and muscle healing direction while noting human efficacy is not confirmed
- Chang et al. 2014 - Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts, Molecules. Mechanistic tendon-fibroblast study supporting growth-hormone receptor expression and tendon repair signaling
- Hsieh et al. 2017 - Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation, Journal of Molecular Medicine. Preclinical angiogenesis mechanism: VEGFR2/Akt/eNOS activation and blood-flow recovery in rat ischemic muscle
- Sikiric/Drmic et al. 2013 - Toxicity by NSAIDs. Counteraction by Stable Gastric Pentadecapeptide BPC 157, Current Pharmaceutical Design. Publisher page confirms NSAID-toxicity counteraction direction in preclinical and review context
- Seiwerth et al. 2021 - Stable Gastric Pentadecapeptide BPC 157 and Wound Healing, Frontiers in Pharmacology. Review of wound healing, fistula, bleeding-disorder, and tissue-repair mechanisms in preclinical BPC-157 literature
- Japjec et al. 2021 - Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats, Biomedicines. Rat myotendinous-junction study supporting preclinical muscle-to-tendon repair direction
- Zhang et al. 2026 - BPC157 drives angiogenesis through FBXO22-dependent stabilization of BACH1, Cell Communication and Signaling. New 2026 mechanism paper identifies FBXO22-BACH1 signaling in endothelial proliferation and angiogenic repair models
- FDA 2026 - Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act. April 22, 2026 FDA update removed BPC-157 from Category 2 after nomination withdrawal and scheduled PCAC review for July 23, 2026
- FDA 2026 - Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA page frames risk concerns for bulk substances and lists withdrawn nominations separately from current Category 2 entries
- WADA 2026 - The Prohibited List: S0 Non-Approved Substances. WADA lists BPC-157 under S0 non-approved substances, prohibited for covered athletes at all times
Holistic Evidence Profile
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Medium
Citations: Vasireddi 2025, Matek 2026, McGuire 2025, Jozwiak 2025, Lee 2025, Sikiric 2018, Gwyer 2019, Zhang 2026
Pre-RCT-Era Pharmacology and Use
Confidence: Emerging
Citations: Sikiric 2018, Gwyer 2019, Seiwerth 2021, FDA 2026, WADA 2026
Traditional Medicine Systems
Confidence: Low
Holistic Evidence for BPC-157
The three evidence lenses disagree in a useful way. Modern science gives BPC-157 a coherent preclinical repair story across GI, tendon, muscle, vascular, wound, and nerve models, but human evidence remains sparse. Historical adoption shows unusually strong athlete and gray-market interest plus regulatory attention, but that is not the same as clinical proof. Traditional evidence is effectively absent because BPC-157 is synthetic and recent. Honest synthesis: BPC-157 is one of the more promising investigational repair peptides, but the score depends on animal evidence, mechanism, and user experience more than mature clinical medicine.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- hs-CRP Baseline (pre-protocol) During | Expected Down
- ALT During | Expected Stable
- AST During | Expected Stable
- IGF 1 During | Expected Up
- Fibrinogen During | Expected Watch
Pulse Dimensions to Watch
- Body During | Expected Up | Primary
- Energy During | Expected Up | Secondary
- Calm During | Expected Stable | Tertiary
Subjective Signals (Daily Voice Card)
- Injury Pain Scale 1-5 | During | Expected Down
- Range Of Motion Scale 1-5 | During | Expected Up
- Injection-Site Irritation Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Injection-site infection
- Rapidly worsening swelling or pain
Other interventions for Injury Recovery
📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 2.725 − 0.955 = 1.770
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (1.770 / 5) × 5 = 6.8 / 10
